# REal-life ON PARKinson's - ITaly (REONPARK-IT)

> **NCT07403799** · — · RECRUITING · sponsor: **Bial - Portela C S.A.** · enrollment: 200 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Opicapone 50 mg

## Key facts

- **NCT ID:** NCT07403799
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2028-10-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07403799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07403799, "REal-life ON PARKinson's - ITaly (REONPARK-IT)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07403799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*